Ebola Virus Disease (The Killer Virus): Another Threat to Humans and Bioterrorism: Brief Review and Recent Updates.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 4525528)

Published in J Clin Diagn Res on June 01, 2015

Authors

Deepak Passi1, Sarang Sharma2, Shubha Ranjan Dutta3, Pooja Dudeja2, Vivek Sharma4

Author Affiliations

1: Tutor, Department of Oral and Maxillofacial Surgery, ESIC Dental College and Hospital , Rohini, Delhi, India .
2: Associate Professor, Department of Conservative Dentistry and Endodontics, ESIC Dental College and Hospital , Rohini, Delhi, India .
3: Assistant Professor, Department of Oral and Maxillofacial Surgery, M B Kedia Dental College , Birgunj, Nepal .
4: Assistant Professor, Department of Conservative Dentistry and Endodontics, ESIC Dental College and Hospital , Rohini, Delhi, India .

Articles cited by this

Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 8.32

The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A (1996) 7.02

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35

Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med (1999) 5.85

Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis (1997) 4.03

Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis (1999) 3.62

Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol (1999) 3.44

Immunization for Ebola virus infection. Nat Med (1998) 3.27

Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15

Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl (1996) 2.69

Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire. Lancet (1977) 2.65

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64

Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58

Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol (2006) 2.39

Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 2.31

Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol (1996) 2.26

Ebola virus pathogenesis: implications for vaccines and therapies. J Virol (2003) 2.25

Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis (1985) 2.02

Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis (2006) 1.62

Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs (2013) 1.57

Clinical features and pathobiology of Ebolavirus infection. J Autoimmun (2014) 1.56

Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J Pathol (1985) 1.52

Ebola viral hemorrhagic disease outbreak in West Africa- lessons from Uganda. Afr Health Sci (2014) 1.33

Intracellular events and cell fate in filovirus infection. Viruses (2011) 1.01

Correlates of immunity to filovirus infection. Viruses (2011) 0.91

Clinical aspects of African viral hemorrhagic fevers. Rev Infect Dis (1989) 0.85

Articles by these authors

Benefits of Alcohol on Arsenic Toxicity in Rats. J Clin Diagn Res (2017) 0.75